DXCM - DexCom, Inc.
Great Lakes Advisors LLC purchased a new position in shares of DexCom, Inc. (NASDAQ: DXCM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,472 shares of the medical device company's stock, valued at approximately $369,000. Other hedge funds also recently added to
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Dan Deming discusses why he sees sideways action in the stock market continuing through next week, noting anticipating for the Fed's Jackson Hole meeting. As for Thursday's Big 3, he sees an opportunity in Parker-Hannifin (PH) closing its stock gap, Dexcom (DXCM) maintaining recent upward momentum, and Union Pacific (UNP) becoming a leader in the railroad industry's comeback.
Aurora Investment Counsel bought a new stake in DexCom, Inc. (NASDAQ: DXCM) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 34,744 shares of the medical device company's stock, valued at approximately $2,340,000. DexCom comprises 1.2% of Aurora Investment Counsel's investment portfolio, making
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.
DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.
DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.
DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.
From a technical perspective, DexCom (DXCM) is looking like an interesting pick, as it just reached a key level of support. DXCM recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
GRMN, LTH and DXCM tap the health and fitness boom through premium clubs, connected wearables and glucose sensing as wellness demand grows.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Dexcom (DXCM) delivered strong Q2/26 results with 13.1% revenue growth, 49.7% operating income growth, and raised FY26 guidance. DXCM's growth drivers include G7 system adoption, international expansion, and initiatives like 'Road to 100' targeting broader diabetes coverage. Margin improvements, ongoing share buybacks, and a robust balance sheet support DXCM's growth and capital allocation strategy.
DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.
Revenue: Worldwide revenue of $1.31 billion, up 13% reported and 12% organic year-over-year.US Revenue: $933 million, up 11% year-over-year.International Revenu
DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcript
DexCom NASDAQ: DXCM reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and share gains across several patient groups and markets.
DexCom (DXCM) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.48 per share a year ago.
Medical device maker Dexcom raised its full-year revenue forecast and beat quarterly estimates on Thursday, banking on sustained demand for its continuous glucose monitors that track blood sugar levels, sending shares of the company up over 4% in extended trading.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results.